Abstract: The invention provides medical or industrial light source devices, for example, an endoscope. A light source device includes: a light source emitting a light beam; a concentrator including a pair of Fresnel lenses with corrugated surfaces and concentrating the emitted light beam, the corrugated surfaces of the Fresnel lenses facing each other, and a light guide guiding the concentrated light beam. The corrugated surfaces of the pair of Fresnel lenses may be in contact with each other and one end of the light guide may be disposed at a focal point of the concentrated light beam.

Abstract: The invention provides medical or industrial light source devices, for example, an endoscope. A light source device includes: a light source emitting a light beam; a concentrator including a pair of Fresnel lenses with corrugated surfaces and concentrating the emitted light beam, the corrugated surfaces of the Fresnel lenses facing each other, and a light guide guiding the concentrated light beam. The corrugated surfaces of the pair of Fresnel lenses may be in contact with each other and one end of the light guide may be disposed at a focal point of the concentrated light beam.

Abstract: Provided is a shoe sole member formed by at least two types of polymer compositions, a first composition and a second polymer composition, including: a first part formed by the first polymer composition; a second part formed by the second polymer composition; and a third part formed by a mixture of the first polymer composition and the second polymer composition between the first part and the second part.

Abstract: Provided is a shoe sole member formed by at least two types of polymer compositions, a first composition and a second polymer composition, including: a first part formed by the first polymer composition; a second part formed by the second polymer composition; and a third part formed by a mixture of the first polymer composition and the second polymer composition between the first part and the second part.

Abstract: Provided is a shoe sole member formed by at least two types of polymer compositions, a first composition and a second polymer composition, including: a first part formed by the first polymer composition; a second part formed by the second polymer composition; and a third part formed by a mixture of the first polymer composition and the second polymer composition between the first part and the second part.

Abstract: A lactic acid bacterial strain Enterococcus durans (E. durans) HS-08 or a processed product thereof is provided having IgA production promoting effects, immunostimulation, and antiallergic effects. The product also provides an inhibitory effect on proliferation of harmful bacteria and/or pathogenic bacteria, protective effect on the mucosa, enhancing effect on short chain fatty acid production, enhancing effect on organic acid production, upregulating effect on the expression of the GRP43 gene, modulating effect on plant growth, preventive effect on plant lodging, adjustment effect on the umami taste of plants, promoting effect on animal growth, or enhancement of immunity in animals.

Abstract: Provided is a shoe sole member including: a first foam member containing a first resin; and a second foam member containing a second resin, wherein the first foam member and the second foam member are fused, and the second resin has a melting point higher than that of the first resin by 20° C. or more.

Abstract: Provided is a shoe sole member including: a first foam member containing a first resin; and a second foam member containing a second resin, wherein the first foam member and the second foam member are fused, and the second resin has a melting point higher than that of the first resin by 20° C. or more.

Abstract: Provided is a shoe sole member formed by at least two types of polymer compositions, a first composition and a second polymer composition, including: a first part formed by the first polymer composition; a second part formed by the second polymer composition; and a third part formed by a mixture of the first polymer composition and the second polymer composition between the first part and the second part.

Abstract: A method of manufacturing a substrate includes applying solder resist ink containing a mixing resin of epoxy-based resin and acrylic-based resin on at least one surface of a substrate body to form a solder resist layer, and irradiating a predetermined portion of the solder resist layer with ultraviolet rays and controlling an amount of irradiation of the ultraviolet rays irradiated to the predetermined of the solder resist layer to form the predetermined portion in transmissivity that transmits light.

Abstract: A method of manufacturing a substrate includes applying solder resist ink containing a mixing resin of epoxy-based resin and acrylic-based resin on at least one surface of a substrate body to form a solder resist layer, and irradiating a predetermined portion of the solder resist layer with ultraviolet rays and controlling an amount of irradiation of the ultraviolet rays irradiated to the predetermined of the solder resist layer to form the predetermined portion in transmissivity that transmits light.

Abstract: The present invention relates to a compound represented by formula [I]: wherein: R1 is hydrogen, halogen, lower alkyl or cyano; Ring A is an optionally substituted heterocyclic group; Ring B is an optionally substituted 3 to 6-membered monocyclic group; and Y is optionally substituted amino, optionally substituted cyclic amino, optionally substituted aliphatic 3 to 6-membered monocyclyloxy, optionally substituted lower alkyl or optionally substituted lower alkyl-O—, or a pharmaceutically acceptable salt thereof, and to their use as PDE10 inhibitor.

Abstract: The present invention relates to a compound represented by formula [I]: wherein: R1 is hydrogen, halogen, lower alkyl or cyano; Ring A is an optionally substituted heterocyclic group; Ring B is an optionally substituted 3 to 6-membered monocyclic group; and Y is optionally substituted amino, optionally substituted cyclic amino, optionally substituted aliphatic 3 to 6-membered monocyclyloxy, optionally substituted lower alkyl or optionally substituted lower alkyl-O—, or a pharmaceutically acceptable salt thereof, and to their use as PDE10 inhibitor.

Abstract: (2S)-[4-(Carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide hydrobromide and a crystal thereof, which resist easy weight change caused by vapor sorption as compared to a free form, and are superior as drug substances of pharmaceutical products, and a production intermediate therefor are provided.

Abstract: A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.

Abstract: A reversibly immortalized human pancreatic islet cell line containing an hTERT gene and an SV40T gene each interposed between a pair of LoxP sequences, characterized in that it is capable of producing insulin and enhancing expression of insulin after excising the hTERT gene and the SV40T gene, in particular, NAKT-13 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Sep. 4, 2003, accession number: FERM BP-08461) or a passage cell line thereof; a human pancreatic islet cell obtained by excising the hTERT gene and the SV40T gene from the reversibly immortalized human pancreatic islet cell line or passage cell line thereof; and use of these cells. By using the reversibly immortalized human pancreatic islet cell line of the invention insulin-producing cells can be easily and surely obtained in a number enough to meet the demand.

Abstract: (2S)-[4-(Carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide hydrobromide and a crystal thereof, which resist easy weight change caused by vapor sorption as compared to a free form, and are superior as drug substances of pharmaceutical products, and a production intermediate therefor are provided.

Abstract: A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Abstract: A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.